Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer

Annals of Oncology

Volumn 29, Issue 1, 2018, Pages 145-153

  Fribbens, C ^a,b   Garcia Murillas, I ^a   Beaney, M ^a   Hrebien, S ^a   O'Leary, B ^a   Kilburn, L ^a   Howarth, K ^c   Epstein, M ^c   Green, E ^c   Rosenfeld, N ^c,d,e   Ring, A ^b   Johnston, S ^b   Turner, N ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c Babraham   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Breast cancer; ctDNA; ESR1; KRAS

Indexed keywords

AROMATASE INHIBITOR; CHLOROPLAST DNA; CIRCULATING TUMOR DNA; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN; KRAS PROTEIN, HUMAN; PROTEIN P21;

ADULT; ADVANCED CANCER; AGED; AMPLICON SEQUENCING; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; DNA DETERMINATION; DROPLET DIGITAL POLYMERASE CHAIN REACTION; ESR1 GENE; GENE; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC RESISTANCE; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; METASTATIC BREAST CANCER; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SEQUENCE ANALYSIS; BLOOD; BREAST TUMOR; DISEASE EXACERBATION; DRUG RESISTANCE; FEMALE; GENETICS; METASTASIS; MIDDLE AGED; MUTATION; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AROMATASE INHIBITORS; BREAST NEOPLASMS; CIRCULATING TUMOR DNA; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 85041200626     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdx483     Document Type: Article

References (18)

1. Misale S, Yaeger R, Hobor S et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486(7404): 532-536.
2. Misale S, Di Nicolantonio F, Sartore-Bianchi A et al. Resistance to anti- EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov 2014; 4(11): 1269-1280.
3. Remon J, Caramella C, Jovelet C et al. Osimertinib benefit in EGFRmutant NSCLC patients with T790M-mutation detected by circulating tumour DNA. Ann Oncol 2017; 28(4): 784-790.
4. Kobayashi S, Boggon TJ, Dayaram T et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352(8): 786-792.
5. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490(7418): 61-70.
6. Toy W, Shen Y, Won H et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet 2013; 45(12): 1439-1445.
7. Schiavon G, Hrebien S, Garcia-Murillas I et al. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci Transl Med 2015; 7(313): 313ra182.
8. Fribbens C, O'Leary B, Kilburn L et al. Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. J Clin Oncol 2016; 34(25): 2961-2968.
9. Clatot F, Perdrix A, Augusto L et al. Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor. Oncotarget 2016; 7(46): 74448-74459.
10. Forshew T, Murtaza M, Parkinson C et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 2012; 4(136): 136ra68.
11. Garcia-Murillas I, Schiavon G, Weigelt B et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med 2015; 7(302): 302ra133.
12. Johnston SR, Kilburn LS, Ellis P et al. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptorpositive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol 2013; 14(10): 989-998.
13. Fumagalli D, Wilson TR, Salgado R et al. Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers. Ann Oncol 2016; 27(10): 1860-1866.
14. Lajos Pusztai JC, Young L, Schrock AB, Hartmaier R, Frampton GM, Gay LM, Stephens P, Miller VA, Ali SM, Ross JS, Vahdat LT, O'Shaughnessy J. Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with metastatic breast cancer (mBC). In ASCO Annual Meeting (Abstr 1016). 2017.
15. Steensma DP, Bejar R, Jaiswal S et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 2015; 126(1): 9-16.
16. Genovese G, Kahler AK, Handsaker RE et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014; 371(26): 2477-2487.
17. Gutierrez MC, Detre S, Johnston S et al. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 2005; 23(11): 2469-2476.
18. Cui Y, Parra I, Zhang M et al. Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. Cancer Res 2006; 66(11): 5950-5959.